Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway

Detalles Bibliográficos
Autores principales: Zhang, Fengli, Chen, Huixiao, Du, Jing, Wang, Bin, Yang, Lixiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Retraction Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009266/
https://www.ncbi.nlm.nih.gov/pubmed/33762564
http://dx.doi.org/10.12659/MSM.932331
_version_ 1783672845869514752
author Zhang, Fengli
Chen, Huixiao
Du, Jing
Wang, Bin
Yang, Lixiao
author_facet Zhang, Fengli
Chen, Huixiao
Du, Jing
Wang, Bin
Yang, Lixiao
author_sort Zhang, Fengli
collection PubMed
description
format Online
Article
Text
id pubmed-8009266
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-80092662021-04-01 Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway Zhang, Fengli Chen, Huixiao Du, Jing Wang, Bin Yang, Lixiao Med Sci Monit Retraction Note International Scientific Literature, Inc. 2021-03-25 /pmc/articles/PMC8009266/ /pubmed/33762564 http://dx.doi.org/10.12659/MSM.932331 Text en © Med Sci Monit, 2021 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Retraction Note
Zhang, Fengli
Chen, Huixiao
Du, Jing
Wang, Bin
Yang, Lixiao
Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
title Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
title_full Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
title_fullStr Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
title_full_unstemmed Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
title_short Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
title_sort retracted: anticancer activity of metformin, an antidiabetic drug, against ovarian cancer cells involves inhibition of cysteine-rich 61 (cyr61)/akt/mammalian target of rapamycin (mtor) signaling pathway
topic Retraction Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009266/
https://www.ncbi.nlm.nih.gov/pubmed/33762564
http://dx.doi.org/10.12659/MSM.932331
work_keys_str_mv AT zhangfengli retractedanticanceractivityofmetforminanantidiabeticdrugagainstovariancancercellsinvolvesinhibitionofcysteinerich61cyr61aktmammaliantargetofrapamycinmtorsignalingpathway
AT chenhuixiao retractedanticanceractivityofmetforminanantidiabeticdrugagainstovariancancercellsinvolvesinhibitionofcysteinerich61cyr61aktmammaliantargetofrapamycinmtorsignalingpathway
AT dujing retractedanticanceractivityofmetforminanantidiabeticdrugagainstovariancancercellsinvolvesinhibitionofcysteinerich61cyr61aktmammaliantargetofrapamycinmtorsignalingpathway
AT wangbin retractedanticanceractivityofmetforminanantidiabeticdrugagainstovariancancercellsinvolvesinhibitionofcysteinerich61cyr61aktmammaliantargetofrapamycinmtorsignalingpathway
AT yanglixiao retractedanticanceractivityofmetforminanantidiabeticdrugagainstovariancancercellsinvolvesinhibitionofcysteinerich61cyr61aktmammaliantargetofrapamycinmtorsignalingpathway

Ejemplares similares